| Literature DB >> 31541139 |
Diogo N de Oliveira1, Estela O Lima1, Carlos F O R Melo1, Jeany Delafiori1, Tatiane M Guerreiro1, Rafael G M Rodrigues1, Karen N Morishita1, Cynthia Silveira2, Stéfanie Primon Muraro3, Gabriela Fabiano de Souza3, Aline Vieira3, Antônio Silva4, Rosângela F Batista4, Maria J R Doriqui4, Patricia S Sousa4, Guilherme P Milanez3, José L Proença-Módena3, Denise P Cavalcanti2, Rodrigo R Catharino5.
Abstract
Zika virus (ZIKV) has emerged as one of the most medically relevant viral infections of the past decades; the devastating effects of this virus over the developing brain are a major matter of concern during pregnancy. Although the connection with congenital malformations are well documented, the mechanisms by which ZIKV reach the central nervous system (CNS) and the causes of impaired cortical growth in affected fetuses need to be better addressed. We performed a non-invasive, metabolomics-based screening of saliva from infants with congenital Zika syndrome (CZS), born from mothers that were infected with ZIKV during pregnancy. We were able to identify three biomarkers that suggest that this population suffered from an important inflammatory process; with the detection of mediators associated with glial activation, we propose that microcephaly is a product of immune response to the virus, as well as excitotoxicity mechanisms, which remain ongoing even after birth.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31541139 PMCID: PMC6754385 DOI: 10.1038/s41598-019-49796-5
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1OPLS-DA score plots indicating clear separation between the group of infants with congenital zika syndrome (green) and the control group (red). The statistical model was able to distinguish the high-resolution mass spectrometry-generated datasets from both the positive (A) and negative (B) ion modes, in a strong indication that the chemical composition of the two groups is different.
Identified species, elected as biomarkers for the CZS group.
| Compound | Experimental Mass | Theoretical Mass | Error | Adduct | METLIN ID |
|---|---|---|---|---|---|
| Ethyl-PGE2, and/or Dimethyl-PGD2, and/or Dimethyl-PGE2, and/or Dihomo-PGI2, and/or Dihomo-PGD2, and/or Didehydro-dimethyl-PGE1, and/or Dihomo-PGE2 | 403.2461 | 403.2455 | −1.5 | [M + Na]+ | 36221, 36123, 36136, 45950, 36205, 3014 and 36204 |
| Hepoxilin A3 and/or B3 | 359.2192 | 359.2198 | 1.7 | [M + Na]+ | 7070 and 7071 |
| 15-deoxy-δ-12,14-PGJ2 | 351.1727 | 351.1732 | 1.4 | [M+Cl]− | 36099 |
Figure 2A conception of metabolic pathways that are putatively activated in response to ZIKV pathogenesis, as suggested by the markers from OPLS-DA (in red). Arachidonic acid (AA) is the main precursor activated in this mechanism, with two main cascades unfolding upon activation: prostaglandin metabolism (and its derivatives), and hepoxilin metabolism. All highlighted mediators are linked with response to neural damage and show the organism attempting to attenuate nervous system deterioration. AA: arachidonic acid; 12(S)-HPETE: 12-hydroperoxyicosatetraenoic acid; 12- HPTEH: HxA3 and HxB3: hepoxilin A3 and B3; PTGS1: prostaglandin-endoperoxide synthase 1 (COX-1); PGG2: prostaglandin G2; PGH2: prostaglandin H2; PTGDS: prostaglandin-H2 D-isomerase; PGD2: prostaglandin D2; PGJ2: prostaglandin J2; Δ12-PGJ2: delta-12-prostaglandin J2.
Figure 3Extracellular DNA quantification from ZIKV-infected human neutrophils. (A–C) Human neutrophils (1 × 105/300 μL) were stimulated with PMA (100 nM) or infected with ZIKV (MOI 2) for 6 hours in 8-chamber culture. Cells were stained for DNA with Hoechst 33342. Scale bars = 100 μm, Magnification = 20×. (D,E) Neutrophils (2 × 106/mL) were stimulated with ZIKV, UV-ZIKV or PMA or left unstimulated for 6 hours. Extracellular DNA (μg/mL) was quantified in culture supernatants and fold number of concentrations was evaluated using the negative control (NCrl) as reference. Data are representative of 2 independent experiments performed in triplicates and represent mean ± SD. Data were analyzed with Kruskal-Wallis test. *p < 0.05, **p < 0.01.